肺表面活性物质联合鼻塞持续正压通气治疗新生儿呼吸窘迫综合征

目的探讨应用国产肺表面活性物质（PS）珂立苏联合鼻塞持续正压通气（CPAP）治疗新生儿呼吸窘迫综合征（NRDS）的临床疗效。方法对43例确诊为NRDS的患者早期给予气管插管-PS-拔管应用CPAP（INSURE技术）治疗，观察治疗前后临床症状，血气分析的变化及并发症情况。结果43例患儿经INSURE技术治疗后临床症状明显改善，6、24、48h血pH值，氧分压（PO2），二氧化碳分压（PCO2），吸入氧浓度（FiO2），呼气未正压（PEEP）均较用药前明显改善，差异有统计学意义（P〈0．05）。结论肺表面活性物质联合鼻塞持续正压通气可发挥协同作用，能减轻NRDS的程度，改善血氧饱和度，减少机械通气的应用。

Pulmonary surfactant combined with CPAP in the treatment of neonatal respiratory distress syndrome

Objective To study the clinical of effect of pulmonary surfactant combined with CPAP on neonatal respiratory distress syndrome. Methods Forty-three infants admitted into Huaibei people＇ s hospital with a confirmed diagnosis of neonatal respiratory distress syndrome were treated by intubation-surfactant-extubation （ INSURE）, and then the clinical syndrome, the blood gas analysis of infants and the complications were observed. Results After 6 h, 24 h, 48 h of treatment, the clinical syndrome and pH, PO2, PCO2, FiO2, PEEP of infants were improved significantly （ P 〈 0.05 ）. Conclusion The combined use of exogenous PS and CPAP can exert synergetic therapeutic effect on neonatal respiratory distress syndrome, which can reduce the extents of NRDS and improve oxygen saturation and ventitalion.